Skip to content
  • Home
  • Need
  • Solution
    • Anagrelide
    • Silica matrix technology
  • Board
    • Harri Sihto, Ph.D.
    • Heikki Joensuu, M.D., Ph.D.
    • Olli-Pekka Pulkka, M.Sc.
    • Olli Kallioniemi, M.D., Ph.D.
    • Pekka Simula, M.Sc.
  • News
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram

Sartar Therapeutics – Novel targeted therapy for GIST

  • Home
  • Need
  • Solution
    • Anagrelide
    • Silica matrix technology
  • Board
    • Harri Sihto, Ph.D.
    • Heikki Joensuu, M.D., Ph.D.
    • Olli-Pekka Pulkka, M.Sc.
    • Olli Kallioniemi, M.D., Ph.D.
    • Pekka Simula, M.Sc.
  • News
Search box

Sartar won HealthBIO pitching competition 9.10.2017

October 24, 2017November 7, 2017 by ollipulkka

Sartar Therapeutics participated to the HealthBIO pitching competition and won it.

http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/

 

Related

Post navigation

Previous Entry:BIO-Europe Berlin November 6–8, 2017
Next Entry:Sartar was awarded a U.S. patent 16.10.2017
Go to the top

Contact

Sartar Therapeutics Ltd.
Biomedicum, B418b
Haartmaninkatu 8
00290 Helsinki
Tel. +358 9 471 71913
info@sartartherapeutics.com

Y-tunnus: 2754654-8
Sartar therapeutics Ltd.

Search

Create a website or blog at WordPress.com
  • Facebook
  • LinkedIn
  • Twitter
  • Instagram